GlassScriptPhysician profile
Adam R Jaffe
NPI 1740441286
$11,391.60
in general payments reported to CMS, 2019-2025
73 companies · $2,207 in 2025
The $2,207 reported for 2025 was more than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,798 · 2020: $852 · 2021: $1,307 · 2022: $1,605 · 2023: $1,588 · 2024: $2,035 · 2025: $2,207.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,553 · Education: $277.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,552.61 |
| Education | $277.24 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,196.72 | 2021-2025 | |
| Biogen, INC. | $828.50 | 2019-2025 | Vumerity, Tysabri, Avonex |
| Ucb, INC. | $790.91 | 2019-2025 | Briviact, Fintepla, Rystiggo |
| Novartis Pharmaceuticals Corporation | $754.19 | 2019-2025 | |
| Upsher-Smith Laboratories LLC | $480.79 | 2019-2023 | |
| Lundbeck LLC | $386.04 | 2019-2025 | Vyepti |
| Alexion Pharmaceuticals, INC. | $350.13 | 2019-2025 | Ultomiris, Soliris |
| Acadia Pharmaceuticals INC | $346.72 | 2019-2025 | Nuplazid, Daybue |
| Pfizer INC. | $334.36 | 2023-2025 | |
| Emd Serono, INC. | $315.72 | 2019-2025 | Mavenclad |
| Jazz Pharmaceuticals INC. | $267.68 | 2022-2025 | Epidiolex |
| Tg Therapeutics, INC. | $258.64 | 2023-2025 | |
| Allergan, INC. | $240.11 | 2019-2022 | |
| Biohaven Pharmaceuticals, INC. | $217.02 | 2021 | |
| Celgene Corporation | $216.51 | 2021-2025 | Zeposia |
Show all 73 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Adam Jaffe listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.